June 30, 2026Journal of the American College of Cardiology

Transplantation of Human Embryonic Stem Cell-Derived Cardiomyocytes Improves Myocardial Performance in Infarcted Rat Hearts

Q: What is the clinical evidence from this study?

Study design: RCT. Population: myocardial infarction. Intervention: human embryonic stem cell-derived cardiomyocytes (hESC-CMs) vs. saline, undifferentiated hESCs, or noncardiomyocyte hESC derivatives. Primary outcome: fractional shortening.

View Full Paper

Ask AI

Bookmark

Key result

hESC-CM transplantation improves fractional shortening by ~22% after myocardial infarction compared to saline.

Why the study?

Does transplantation of hESC-CMs improve myocardial performance in infarcted rat hearts?

Key Points

The study aims to evaluate the engraftment and impact of human embryonic stem cell-derived cardiomyocytes on heart function in a rat model of myocardial infarction.
Immunosuppressed rat hearts were randomized for injection with either hESCs, hESC-derived cardiomyocytes, noncardiomyocyte hESC derivatives, or saline.
Histological analysis and echocardiography assessed the structural and functional outcomes of cell grafting.
Experimental timeline involved injections conducted 7 to 10 days post-coronary ligation.
HESC-CMs transplantation improved fractional shortening by 22% (from 21 +/- 2% to 25 +/- 3%), while saline and nonmyocyte groups showed functional deterioration (50% and 30%, respectively).
Grafted hESC-CMs survived, proliferated, and formed functional connections with host tissue.
Walls motion score index and LV diastolic dimensions significantly improved in the hESC-CM group compared to controls.

Study Design

Type

RCT

Randomization

randomized

Structured PICO

Does transplantation of hESC-CMs improve myocardial performance in infarcted rat hearts?

Population

Immunosuppressed healthy and infarcted rat hearts randomized 7 to 10 days after coronary ligation.

Intervention

Injection of ex vivo pre-differentiated human embryonic stem cell-derived cardiomyocytes (hESC-CMs)

Comparator

Injection of undifferentiated hESCs, noncardiomyocyte hESC derivatives, or saline

Outcome

Structural and functional consequences of cell grafting (assessed by detailed histological analysis and sequential echocardiography)surrogate

Main Result

Absolute Event Rate: 25% vs 10%

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Transplantation of human embryonic stem cell-derived cardiomyocytes in infarcted rat hearts forms stable grafts, attenuates remodeling, and improves myocardial function, demonstrating potential for cell-based myocardial repair.

Cite This Study

Caspi et al. (2007) conducted an RCT in myocardial infarction. human embryonic stem cell-derived cardiomyocytes (hESC-CMs) vs. saline, undifferentiated hESCs, or noncardiomyocyte hESC derivatives was evaluated on fractional shortening. Transplantation of hESC-CMs in infarcted rat hearts improved fractional shortening by 22% (from 21% to 25%), compared to a 50% deterioration (from 20% to 10%) with saline.

synapsesocial.com/papers/6a43de68798ce7bb980879b4 https://doi.org/10.1016/j.jacc.2007.07.054

View Full Paper

Ask AI

Bookmark

Transplantation of Human Embryonic Stem Cell-Derived Cardiomyocytes Improves Myocardial Performance in Infarcted Rat Hearts

Key Points

Study Design

Structured PICO

Main Result

Discussion

Implication

Cite This Study

Transplantation of Human Embryonic Stem Cell-Derived Cardiomyocytes Improves Myocardial Performance in Infarcted Rat Hearts

Key Points

Study Design

Structured PICO

Main Result

Discussion

Implication

Cite This Study

Also Consider

Also Consider